Keywords: long-term, data, schering, betaseron, latest, results, double-blind
Long-Term Data On Schering's Betaseron
Article | 31 October 1994
The latest results from a double-blind placebo-controlled trial of Schering Health Care's multiple sclerosis drug Betaseron (recombinant interferon beta-1b), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
